Fenofibrate modifies transaminase gene expression via a peroxisome proliferator activated receptor α-dependent pathway-Reference-Cited by-同舟云学术

Fenofibrate modifies transaminase gene expression via a peroxisome proliferator activated receptor α-dependent pathway

Published:1998-09 Issue:1-2 Volume:98 Page:13-23
ISSN:0378-4274
Container-title:Toxicology Letters
language:en
Short-container-title:Toxicology Letters

Author:

Edgar Alan D.,Tomkiewicz Céline,Costet Philippe,Legendre Christiane,Aggerbeck Martine,Bouguet Jacqueline,Staels Bart,Guyomard Claire,Pineau Thierry,Barouki Robert

Publisher

Elsevier BV

Subject

Toxicology,General Medicine

Reference47 articles.

1. Regulation of the cytosolic aspartate aminotransferase housekeeping gene promoter by glucocorticoids, cAMP, and Insulin;Aggerbeck;Biochemistry,1993

2. Fenofibrate, a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in dyslipidemia;Balfour;Drugs,1990

3. Regulation of cytosolic aspartate aminotransferase mRNAs in the Fao rat hepatoma cell line by dexamethasone, insulin and cyclic AMP;Barouki;Eur. J. Biochem.,1989

4. Sterol regulation of fatty acid synthase promoter: Coordinate feedback regulation of two major lipid pathways;Bennett;J. Biol. Chem.,1995

5. Effects of chlorophenoxyisobutyrate with and without androsterone on the serum lipids, fat tolerance and uric acid;Berkowitz;Metabolism,1965

Cited by 70 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Fenofibrate normalizes alkaline phosphatase and improves long-term outcomes in patients with advanced primary biliary cholangitis refractory to ursodeoxycholic acid;Gastroenterología y Hepatología;2023-11

2. Fenofibrate normalizes alkaline phosphatase and improves long-term outcomes in patients with advanced primary biliary cholangitis refractory to ursodeoxycholic acid;Gastroenterología y Hepatología (English Edition);2023-11

3. Novel Selective PPARα Modulator Pemafibrate for Dyslipidemia, Nonalcoholic Fatty Liver Disease (NAFLD), and Atherosclerosis;Metabolites;2023-05-02

4. De Ritis ratio and cardiovascular disease: evidence and underlying mechanisms;Journal of Laboratory and Precision Medicine;2023-01

5. Efficacy and safety of fenofibrate addition therapy in patients with cirrhotic primary biliary cholangitis with incomplete response to ursodeoxycholic acid;Hepatology Communications;2022-10-10